Publications en collaboration avec des chercheurs de Klinikum der Universität München (29)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  2. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

  3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

  4. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

  5. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases

    Melanoma research, Vol. 33, Núm. 2, pp. 155-158

  2. ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

    Molecular Oncology, Vol. 17, Núm. 10, pp. 2000-2016

  3. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

    European Journal of Cancer, Vol. 195

  4. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

    Genome Medicine, Vol. 15, Núm. 1

  5. Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

    Molecular Oncology, Vol. 17, Núm. 6, pp. 1060-1075

  6. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

    Cancer Treatment Reviews, Vol. 119

  7. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis

    Radiotherapy and Oncology, Vol. 186

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  2. Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?

    European Journal of Cancer, Vol. 171, pp. 25-42

  3. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?

    Journal of Clinical Oncology

  3. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  4. ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study

    Frontiers in Medicine, Vol. 8

  5. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495